1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. SUDEEP PHARMA LTD.
Sudeep Pharma Ltd.
NSE: SUDEEPPHRM | BSE: 544619

Sudeep Pharma Live Share Price Today, Share Analysis and Chart

Expensive Rocket
aboutSudeep Pharma Ltd. is a manufacturer of mineral-based excipients and specialty ingredients serving the pharmaceutical, food, and nutritional industries. The company specializes in calcium-based phosphates and various mineral actives, operating from i... Read More
US FDA InspectionsANDA Approvals
Ask AI about Sudeep Pharma
1068.30-61.80(-5.47%)
245.6K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
60.2 / 100
Expensive RocketThese stocks have good momentum, but are expensive with average financialsView SimilarEmbed DVM
Analyst Price Target
No estimates available

16

S

9

W

5

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

11Positive9Negative

Pass in checklist55.0%

045
55
100

Check P/E Buy Sell Zone

Sell Zone

77.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Sudeep Pharma Stock Price Analysis

Day Price Range

-5.5% 1 Day return
1068.3 (LTP)
1,0601,140
LowHigh

Week Price Range

10.6% 1 Week return
1068.3 (LTP)
930.71,162.5
LowHigh

Month Price Range

-10.6% 1 Month return
1068.3 (LTP)
917.41,249.8
LowHigh

52 Week Price Range

80.2% 1 Year return
1068.3 (LTP)
5241,378
LowHigh
View full Price History/Seasonality

Sudeep Pharma Technical Analysis

Sudeep Pharma EMA & SMA

Bullish+4
6 bullish, 2 bearish
Bullish6
Bearish2
5 Day1068.0
10 Day1052.1
12 Day1052.2
20 Day1063.9
26 Day1072.7
50 Day1073.0
100 Day1005.9
200 Day841

Sudeep Pharma Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202639.8%
Week43.6%
Month47.7%

Sudeep Pharma Active Candlesticks

Evening Star
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Sudeep Pharma Resistance and Support

1089.43
Pivot
First Resistance1118.9
Second Resistance1169.4
Third Resistance1198.9
First Support1038.9
Second Support1009.4
Third Support958.9
Day RSI49.3
Day MACD-20.5
Day MFI57.5
Day MACD Signal Line-31.9

Sudeep Pharma Beta

1 Month-0.7
1 Year-
3 Month-0.2
3 Year-

Sudeep Pharma Price Change Analysis

↓-10.6%
Over 1 Month
LowHigh
917.41249.8
↑24.8%
Over 3 Months
LowHigh
801.41378
↑54.2%
Over 6 Months
LowHigh
624.71378
↑80.2%
Over 1 Year
LowHigh
524.11378
All Technicals →

Sudeep Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Riva Resources Private LimitedPromoter45,570,36040.4 %
Mukul Mahavir AgrawalPublic1,500,1171.3 %
Sbi Healthcare Opportunities FundDii3,215,5902.9 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Sudeep Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIABlockSell04 Aug 2026850562,360NSE
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIBlockSell04 Aug 2026850614,112NSE
GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIOBlockPurchase04 Aug 20268501,176,472NSE
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIBulkSell04 Aug 2026850614,112NSE
GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIOBulkPurchase04 Aug 20268501,176,472NSE
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIABlockSell24 Jul 2026800940,000NSE
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIBlockSell24 Jul 20268001,060,000NSE
SBI MUTUAL FUNDBlockPurchase24 Jul 20268002,000,000NSE
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIABulkSell24 Jul 2026800940,000NSE
NUVAMA CROSSOVER OPPORTUNITIES FUND - SERIES IIIBulkSell24 Jul 20268001,060,000NSE
All deals
All insider trades

Sudeep Pharma Corporate Actions

Sudeep Pharma Dividend history and yield

Sudeep Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Sudeep Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
123 Jul 2026
1.5FINAL23 Jul 2026Equity Share

Sudeep Pharma Board Meetings

Sudeep Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
128 Oct 2026
Quarterly Results-
204 Aug 2026
Quarterly Results-
321 May 2026
Audited Results, Dividend & OthersTo consider other business matters.
406 Feb 2026
Quarterly Results-
519 Dec 2025
Quarterly Results-
All Corporate Actions

Sudeep Pharma Research Reports

Sudeep Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
129 Oct 2026ICICI Securities Limited11001130.1Hold-2.66%-5.47%pdf
220 Nov 2025Hem Securities--IPO Subscribe--%pdf
319 Nov 2025Ventura--IPO Subscribe--%pdf
419 Nov 2025IDBI Capital--IPO Note--%pdf
518 Nov 2025SBI Securities--IPO Subscribe--%pdf
All Reports of Sudeep

Sudeep Pharma Corporate Filings

Sudeep Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
29 Oct 2026
Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Submission of Audio Recording of the Earnings call held on 29th October 2026
PDF
29 Oct 2026
Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Newspaper Advertisement for unaudited Financials for the Quarter and Half Year ended 30th September 2026.
PDF
28 Oct 2026
Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Investor Presentation
Submission of Investors Presentation
PDF
28 Oct 2026
Q2FY27 Quarterly Result Announced for Sudeep Pharma Ltd.
Pharmaceuticals company Sudeep Pharma announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations: For Q2FY27, consolidated revenue from operations reached Rs 19,669.91 lakh, registering a growth of 24.28% QoQ from Rs 15,827.05 lakh in Q1FY27 and an increase of 20.92% YoY from Rs 16,266.62 lakh in Q2FY26. For H1FY27, it stood at Rs 35,496.96 lakh, showing a YoY growth of 23.43% against Rs 28,758.37 lakh in H1FY26. Total income: During Q2FY27, consolidated total income was Rs 20,268.34 lakh, expanding by 23.80% QoQ compared to Rs 16,371.59 lakh in Q1FY27 and growing by 17.27% YoY compared to Rs 17,283.17 lakh in Q2FY26. For H1FY27, it achieved Rs 36,639.93 lakh, up 20.96% YoY from Rs 30,290.77 lakh in H1FY26. Profit before tax (PBT): For Q2FY27, consolidated PBT stood at Rs 7,103.25 lakh, marking a rise of 30.83% QoQ from Rs 5,429.26 lakh in Q1FY27 and 19.31% YoY from Rs 5,953.37 lakh in Q2FY26. For H1FY27, PBT reached Rs 12,532.51 lakh, indicating a 20.96% YoY increase compared to Rs 10,360.57 lakh in H1FY26. Profit after tax (PAT): In Q2FY27, consolidated PAT was Rs 5,181.11 lakh, rising by 27.65% QoQ relative to Rs 4,058.69 lakh in Q1FY27 and increasing by 10.76% YoY from Rs 4,677.82 lakh in Q2FY26. For H1FY27, consolidated PAT stood at Rs 9,239.80 lakh, up 18.39% YoY compared to Rs 7,804.74 lakh in H1FY26. Earnings per Equity Share (EPS): The basic and diluted EPS for Q2FY27 stood at Rs 4.59, marking an advance of 27.86% QoQ from Rs 3.59 in Q1FY27 and 9.29% YoY from Rs 4.20 in Q2FY26. For H1FY27, basic and diluted EPS was Rs 8.18, an expansion of 16.03% YoY against Rs 7.05 in H1FY26. Standalone Financial Highlights: Revenue from operations: Standalone revenue from operations for Q2FY27 was Rs 13,741.31 lakh, translating to a growth of 30.02% QoQ from Rs 10,568.33 lakh in Q1FY27 and an increase of 56.36% YoY from Rs 8,788.16 lakh in Q2FY26. For H1FY27, it was recorded at Rs 24,309.64 lakh, higher by 44.65% YoY relative to Rs 16,805.58 lakh in H1FY26. Total income: For Q2FY27, standalone total income reached Rs 14,792.24 lakh, up 28.09% QoQ compared to Rs 11,548.36 lakh in Q1FY27 and 46.88% YoY compared to Rs 10,070.90 lakh in Q2FY26. For H1FY27, total income stood at Rs 26,340.60 lakh, an expansion of 40.48% YoY against Rs 18,750.28 lakh in H1FY26. Profit before tax (PBT): In Q2FY27, standalone PBT was reported at Rs 5,677.27 lakh, representing a growth of 25.03% QoQ from Rs 4,540.75 lakh in Q1FY27 and a growth of 42.28% YoY from Rs 3,990.32 lakh in Q2FY26. For H1FY27, standalone PBT was Rs 10,218.02 lakh, indicating a YoY gain of 38.59% over Rs 7,372.97 lakh in H1FY26. Profit after tax (PAT): For Q2FY27, standalone PAT recorded at Rs 4,233.93 lakh, growing by 25.16% QoQ from Rs 3,382.85 lakh in Q1FY27 and by 42.36% YoY from Rs 2,974.14 lakh in Q2FY26. For H1FY27, standalone PAT climbed to Rs 7,616.78 lakh, up by 38.62% YoY from Rs 5,494.63 lakh in H1FY26. Earnings per Equity Share (EPS): Basic and diluted standalone EPS for Q2FY27 stood at Rs 3.74, increasing by 24.67% QoQ from Rs 3.00 in Q1FY27 and by 40.07% YoY from Rs 2.67 in Q2FY26. For H1FY27, basic and diluted standalone EPS reached Rs 6.74, up 35.61% YoY compared to Rs 4.97 in H1FY26. Business Highlights: Pharmaceutical, Food, and Nutrition: The segment generated external revenue of Rs 14,249.96 lakh in Q2FY27 (up from Rs 10,841.37 lakh in Q1FY27 and Rs 9,049.85 lakh in Q2FY26), and Rs 25,091.33 lakh during H1FY27. The segment result after accounting for depreciation stood at Rs 5,512.34 lakh for Q2FY27 and Rs 9,514.79 lakh for H1FY27. Speciality Ingredients: This segment brought in external revenue of Rs 5,419.95 lakh in Q2FY27 (compared to Rs 4,985.68 lakh in Q1FY27 and Rs 7,216.77 lakh in Q2FY26), and Rs 10,405.63 lakh during H1FY27. The segment result after accounting for depreciation stood at Rs 1,273.79 lakh for Q2FY27 and Rs 2,362.39 lakh for H1FY27. Result PDF
PDF
28 Oct 2026
Sudeep Pharma Ltd - 544619 - Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026
Submission of Unaudited Financials Results for the Quarter and half year ended 30th September 2026
PDF
VIEW ALL

Sudeep Pharma DocumentsAsk MarketMind AI

Sudeep Pharma Earnings Call

Sudeep Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
29 Oct 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
11 Aug 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
05 Aug 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
05 Aug 2026Sudeep Pharma Results Earnings Call for Q1FY27AudioVideo
28 May 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Sudeep Pharma Annual Reports

Sudeep Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link

Sudeep Pharma Investor Presentations

Sudeep Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
28 Oct 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
04 Aug 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
04 Aug 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
04 Aug 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
21 May 2026Sudeep Pharma Ltd - 544619 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Sudeep Pharma - Company Profile

Sudeep Pharma Management Structure

Sudeep Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Dimple Ashwinbhai MehtaCompany Secretary,Compliance Officer-Mar 26
Mr. Ketan VyasChief Financial Officer-Mar 26
Mr. Julian DunnVice President(Advances.,Materials)-Mar 26
Mr. Sendhil Kumar PaniManaging Director(Subsidiary Company)-Mar 26
Mr. Serkan CelebiManaging Director(Subsidiary Company)-Mar 26

Sudeep Pharma Board of Directors

Sudeep Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Sujit J BhayaniChairman / Executive Director / Managing Director349.99Mar 26
Shanil Sujit BhayaniE D & Wholetime Director174.76Mar 26
Ajay Shrirang KandelkarE D & Wholetime Director92.53Mar 26
Samaresh PandaIndependent Non Exe. Director11.75Mar 26
Reshma PatelIndependent Non Exe. Director11.25Mar 26
Sujit GulatiIndependent Non Exe. Director10Mar 26
S. RaghunandanIndependent Non Exe. Director9.5Mar 26
Milin MehtaNon-Exec & Non-Independent Dir-Mar 26
Dimple Ashwinbhai MehtaCompany Sec. & Compli. Officer-Mar 26
Website: www.sudeeppharma.com

About the company - Business Profile

Sudeep Pharma Ltd. is a manufacturer of mineral-based excipients and specialty ingredients serving the pharmaceutical, food, and nutritional industries. The company specializes in calcium-based phosphates and various mineral actives, operating from its headquarters in Vadodara, Gujarat. It maintains a global presence with sales offices in the USA and Europe, providing products to a diverse customer base across more than 50 countries.

Key Points

  • Key Facts: Founded in 1989, the company is headquartered in Vadodara, Gujarat. It is listed on both the BSE and NSE. The company transitioned from a partnership with JRS Pharma, Germany (strategic partnership started in 2015), to full ownership consolidation after a strategic buyback of stakes in 2024.
  • Operations and Resources: The company operates four manufacturing facilities with a combined annual capacity of 72,246 MT as of June 30, 2025. It is currently developing a greenfield project expected to add 51,200 MT of capacity. Notable assets include proprietary technologies for precision processing and a research-driven manufacturing unit for specialty ingredients.
  • Market Significance: Sudeep Pharma serves industries including Pharmaceuticals, Food & Nutrition, and is diversifying into the Electric Vehicle (EV) sector. It caters to 14 Fortune 500 companies and maintains long-term relationships with its top 10 customers, averaging 16 years.
  • Business Model and Expertise: The company operates on a model of high-purity mineral chemistry and precision processing. It excels in the production of high-quality calcium phosphates and has recently expanded into high-growth segments like battery-grade materials.
  • Revenue Breakdown (FY25):
    • Total Revenue from Operations: Rs. 502.0 Crores.
    • Segmental Revenue: Speciality Ingredients accounted for approximately 34-40% of revenue, while Pharma, Food & Nutrition contributed 60-66% in recent periods.
    • Geographical Revenue: Exports typically contribute between 60% and 71% of total revenue, with the domestic market accounting for the remainder.
  • Technological Advancements: The company utilizes 10 in-house developed technologies and 6 proprietary technologies to drive operational innovation. It has secured product-specific regulatory approvals from the USA and Europe.
  • Hiring and Employees: As of June 30, 2025, the company employs over 700 permanent staff. Recent initiatives include the integration of teams from newly acquired or established business units like Nutrition Supplies Services (NSS).
  • Subsidiaries and Units:
    • Sudeep Nutrition: Focuses on specialty ingredients and blends.
    • Sudeep Advanced Materials Private Limited: A wholly owned subsidiary established to manufacture battery-grade iron phosphate for LFP batteries.
    • NSS (Nutrition Supplies Services): Integrated in 2025 to enhance expertise in infant nutrition and premixes.
  • Strategic Initiatives:
    • Battery Materials: Purchasing land in Dahej, Gujarat, for a manufacturing facility dedicated to battery-grade precursor materials.
    • Capacity Expansion: Planning to increase total capacity to 223,700 MT by FY30 through phased expansions in pharma, specialty ingredients, and iron phosphate.
    • Global Reach: Setting up warehousing operations in the USA and Europe to optimize the supply chain.

References

  1. Investor Presentation Dec 2025
  2. Investor Presentation Feb 2026

Sudeep Pharma FAQ

Sudeep Pharma today is trading in the red, down by 5.47% at ₹1,068.3.
Sudeep Pharma is currently trading down 5.47% on an intraday basis. In the past week the stock rose 10.57%. Stock has been up 24.76% in the past quarter and rose 80.15% in the past year. You can view this in the share price history/seasonality section.
Sudeep Pharma is listed on NSE with the ticker SUDEEPPHRM and on BSE as 544619. It's currently trading on NSE at a share price of ₹1,068.3 and on BSE with a share price of ₹1,066.7.
The market cap of Sudeep Pharma is ₹12,066.3 Cr. as of Oct 30, 2026.
Sudeep Pharma announced a FINAL dividend of 150% which equals ₹1.5 in Jul 23, 2026.To view the full dividend history of Sudeep Pharma click here.
Sudeep Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Sudeep Pharma reported ₹202.68 Cr. in revenue, ₹51.45 Cr. in net profit, and ₹79.22 Cr. in EBITD as of Oct 28, 2026 for Q2 FY26-27.
There are no analyst predictions for stock price target for Sudeep Pharma.
The PE ratio of Sudeep Pharma is 64.07 as of Oct 30, 2026.
The PB ratio of Sudeep Pharma is 13.06 as of Oct 30, 2026.
You can view the latest analyst reports on the Sudeep Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×